Scientific article
English

Delavirdine in combination with zidovudine in treatment of human immunodeficiency virus type 1-infected patients: evaluation of efficacy and emergence of viral resistance in a randomized, comparative phase III trial. The M/3331/0013B Study Group

Published in

Antimicrobial agents and chemotherapy, vol. 44, no. 11, p. 3155-3157

Publication date

2000

Abstract

We compared the activity of delavirdine (DLV) plus zidovudine (AZT) (n = 300) with that of AZT (n = 297) against human immunodeficiency virus type 1 in a randomized, double-blind, placebo-controlled trial. DLV exerted a transient antiviral effect, and mutations for resistance to DLV were found in more than 90% of subjects at week 12. The K103N mutation, which confers nonnucleoside reverse transcriptase inhibitor cross-resistance, was found in 85% of the patients.

Keywords

  • Anti-HIV Agents/ therapeutic use
  • Delavirdine/ therapeutic use
  • Double-Blind Method
  • Drug Resistance, Microbial
  • Drug Therapy, Combination
  • HIV Infections/ drug therapy
  • HIV Reverse Transcriptase/genetics
  • HIV-1/drug effects/genetics
  • Humans
  • Treatment Outcome
  • Zidovudine/therapeutic use

Citation (ISO format)

JOLY, V. et al. Delavirdine in combination with zidovudine in treatment of human immunodeficiency virus type 1-infected patients: evaluation of efficacy and emergence of viral resistance in a randomized, comparative phase III trial. The M/3331/0013B Study Group. In: Antimicrobial agents and chemotherapy, 2000, vol. 44, n° 11, p. 3155–3157.

Main files (1)

Article

Identifiers

Journal ISSN

0066-4804
616views
0downloads

Technical informations

Creation

21/06/2010 10:24:57

First validation

21/06/2010 10:24:57

Update

14/03/2023 15:44:18

Status update

14/03/2023 15:44:17

Last indexation

29/10/2024 15:13:14
All rights reserved by Archive ouverte UNIGE and the University of Geneva
OpenAIRE Indexed & Validated